This study will examine whether noninvasive, transcutaneous vagal nerve stimulation (tcVNS) can help restore consciousness in patients in the operating room and the Post Anesthesia Care Unit (PACU). The study will also investigate if tcVNS can expedite discharge from the PACU and examine whether tcVNS administerd in the PACU helps reduce delirium and depression after surgery. The study will also evaluate whether tcVNS speeds cognitive recovery from emergence of anesthesia and surgery.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Aim 1: Primary Endpoint 1: Determine if administering auricular tcVNS enhances the speed of recovery of anesthesia.
Timeframe: 24 Hours
Aim1:Primary Endpoint 2 : Richmond Agitation Sedation Scale (RASS Score)
Timeframe: 1 Hour
Aim 2: Primary Endpoint 1: Post Anesthesia Care Unit Discharge (PACU)
Timeframe: 3 Hours
Aim 2: Primary Endpoint 2: Discharge from Hospital
Timeframe: From PACU discharge (average of two hours post-surgical end time) to study completion (average of two days)
Aim 3: Primary Endpoint 1: Post Anesthesia Care Unit delirium
Timeframe: From PACU arrival to one hour post-PACU arrival
Aim 3: Primary Endpoint 1a: Post Anesthesia Care Delirium
Timeframe: 30 Days after discharge
Aim3:Primary Endpoint 1b: PHQ-9
Timeframe: 30 days